Breast cancer prognostic test Digistain available to selected UK private patients with reimbursement from Bupa, WPA and Healix

We’re thrilled to announce that Digistain® is now available to selected UK private patients, with reimbursement available though Bupa, WPA Health Insurance & Healix.

Tim Woodman, Medical Director at Bupa’s Policy and Cancer Services, said:

“I’m really excited to be working with Digistain.”

Supported by:

royal society logo
NIHR logo
cancer research uk logo
BIVDA logo

Subscribe to leading news and insights

To stay updated about Digistain’s developments, enter your details opposite. We promise only to send you important news.